Nektar Therapeutics - Asset Resilience Ratio
Nektar Therapeutics (NKTR) has an Asset Resilience Ratio of 76.05% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Nektar Therapeutics (NKTR) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2024)
This chart shows how Nektar Therapeutics's Asset Resilience Ratio has changed over time. See NKTR total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Nektar Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Nektar Therapeutics worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $229.18 Million | 76.05% |
| Total Liquid Assets | $229.18 Million | 76.05% |
Asset Resilience Insights
- Very High Liquidity: Nektar Therapeutics maintains exceptional liquid asset reserves at 76.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nektar Therapeutics Industry Peers by Asset Resilience Ratio
Compare Nektar Therapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Nektar Therapeutics (1997–2024)
The table below shows the annual Asset Resilience Ratio data for Nektar Therapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 69.43% | $210.97 Million | $303.85 Million | +2.02pp |
| 2023-12-31 | 67.42% | $268.34 Million | $398.03 Million | +8.77pp |
| 2022-12-31 | 58.65% | $416.75 Million | $710.60 Million | -4.79pp |
| 2021-12-31 | 63.44% | $708.74 Million | $1.12 Billion | +7.36pp |
| 2020-12-31 | 56.08% | $862.94 Million | $1.54 Billion | -6.05pp |
| 2019-12-31 | 62.13% | $1.23 Billion | $1.98 Billion | +9.09pp |
| 2018-12-31 | 53.04% | $1.14 Billion | $2.15 Billion | -4.22pp |
| 2017-12-31 | 57.26% | $291.37 Million | $508.87 Million | -0.66pp |
| 2016-12-31 | 57.92% | $329.46 Million | $568.87 Million | +7.45pp |
| 2015-12-31 | 50.47% | $253.37 Million | $502.06 Million | -0.59pp |
| 2014-12-31 | 51.05% | $225.46 Million | $441.62 Million | +5.50pp |
| 2013-12-31 | 45.56% | $197.96 Million | $434.53 Million | -5.02pp |
| 2012-12-31 | 50.57% | $251.76 Million | $497.79 Million | +13.34pp |
| 2011-12-31 | 37.24% | $225.86 Million | $606.55 Million | -19.97pp |
| 2010-12-31 | 57.21% | $298.18 Million | $521.23 Million | -3.02pp |
| 2009-12-31 | 60.23% | $346.61 Million | $575.52 Million | +20.37pp |
| 2008-12-31 | 39.86% | $223.41 Million | $560.54 Million | -16.14pp |
| 2007-12-31 | 56.00% | $406.06 Million | $725.10 Million | +4.60pp |
| 2006-12-31 | 51.40% | $394.88 Million | $768.18 Million | +26.37pp |
| 2005-12-31 | 25.03% | $214.93 Million | $858.55 Million | -17.16pp |
| 2004-12-31 | 42.20% | $314.33 Million | $744.92 Million | +6.22pp |
| 2003-12-31 | 35.98% | $221.92 Million | $616.79 Million | -6.73pp |
| 2002-12-31 | 42.71% | $259.09 Million | $606.64 Million | -4.28pp |
| 2001-12-31 | 46.99% | $313.54 Million | $667.24 Million | -8.42pp |
| 2000-12-31 | 55.41% | $348.83 Million | $629.54 Million | +9.22pp |
| 1999-12-31 | 46.19% | $104.75 Million | $226.81 Million | +3.10pp |
| 1998-12-31 | 43.08% | $57.95 Million | $134.50 Million | -28.08pp |
| 1997-12-31 | 71.16% | $85.22 Million | $119.76 Million | -- |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; P… Read more